Suppr超能文献

免疫抑制药物前瞻性撤药12年后的临床移植耐受:嵌合状态与抗供体反应性研究

Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity.

作者信息

Strober S, Benike C, Krishnaswamy S, Engleman E G, Grumet F C

机构信息

Department of Medicine, Stanford University, California 94305-5111, USA.

出版信息

Transplantation. 2000 Apr 27;69(8):1549-54. doi: 10.1097/00007890-200004270-00005.

Abstract

BACKGROUND

Previous studies showed the feasibility of inducing transplantation tolerance to cadaveric renal allografts in patients given pretransplant total lymphoid irradiation (TLI). Microchimerism has been theorized to be an important or necessary factor in long-term graft acceptance and tolerance in humans.

METHODS

A cadaveric renal transplant recipient given pretransplant total lymphoid irradiation and withdrawn from immunosuppressive drugs more than 12 years ago was tested for microchimerism using a sensitive nested polymerase chain reaction technique, and for anti-donor reactivity using the mixed leukocyte reaction and an ELISA screen for anti-HLA antibodies. Donor and recipient were mismatched for all HLA-A, B, and DR antigens.

RESULTS

The "tolerant" recipient had good graft function, no detectable donor-type cells in the blood by polymerase chain reaction analysis, vigorous reactivity to donor stimulator cells in the mixed leukocyte reaction, and no detectable serum anti-HLA antibodies.

CONCLUSIONS

Operational tolerance to HLA-A, B, and DR mismatched organ allografts can be induced prospectively in humans for at least 12 years after withdrawal of immunosuppressive drugs. The allograft can be maintained in the absence of detectable donor microchimerism and in the presence of anti-donor reactivity in the mixed leukocyte reaction, suggesting that neither chimerism nor clonal deletion or anergy of recipient T cells to alloantigens presented by donor Class II HLA molecules is required for persistence of the tolerant state using this total lymphoid irradiation protocol.

摘要

背景

先前的研究表明,对于移植前接受全身淋巴照射(TLI)的患者,诱导对尸体肾移植的移植耐受是可行的。微嵌合体被认为是人类长期移植接受和耐受的一个重要或必要因素。

方法

一名移植前接受全身淋巴照射且在12年多前停用免疫抑制药物的尸体肾移植受者,采用敏感的巢式聚合酶链反应技术检测微嵌合体,并采用混合淋巴细胞反应和ELISA筛选抗HLA抗体检测抗供体反应性。供体和受者在所有HLA - A、B和DR抗原上均不匹配。

结果

这位“耐受”的受者移植肾功能良好,聚合酶链反应分析未在血液中检测到供体类型细胞,在混合淋巴细胞反应中对供体刺激细胞有强烈反应,且未检测到血清抗HLA抗体。

结论

在停用免疫抑制药物后,人类对HLA - A、B和DR不匹配的器官移植可前瞻性地诱导至少12年的操作性耐受。在没有可检测到的供体微嵌合体且混合淋巴细胞反应存在抗供体反应性的情况下,同种异体移植物仍可维持,这表明使用这种全身淋巴照射方案维持耐受状态不需要嵌合体,也不需要受体T细胞对供体II类HLA分子呈递的同种抗原进行克隆清除或失能。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验